Literature DB >> 29730081

Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study.

Tetsuo Shoda1, Ting Wen1, Seema S Aceves2, J Pablo Abonia1, Dan Atkins3, Peter A Bonis4, Julie M Caldwell1, Kelley E Capocelli5, Christina L Carpenter6, Margaret H Collins7, Evan S Dellon8, Michael D Eby1, Nirmala Gonsalves9, Sandeep K Gupta10, Gary W Falk11, Ikuo Hirano9, Paul Menard-Katcher12, Jonathan T Kuhl1, Jeffrey P Krischer6, John Leung4, Vincent A Mukkada13, Jonathan M Spergel14, Michael P Trimarchi1, Guang-Yu Yang15, Nives Zimmermann1, Glenn T Furuta16, Marc E Rothenberg17.   

Abstract

BACKGROUND: Eosinophilic oesophagitis is understood in terms of quantifiable histological, endoscopic, and molecular features. Data are scant for inter-relations of these features and their potential to identify distinct disease endotypes. We aimed to identify clinical-pathological correlations between endoscopic and histological disease variables by transcription profiling of the oesophagus of patients with eosinophilic oesophagitis of varying severity and disease activity states.
METHODS: We did a cross-sectional study across ten hospital sites in the USA associated with the Consortium of Eosinophilic Gastrointestinal Disease Researchers. We analysed oesophageal biopsy specimens taken from paediatric and adult patients with eosinophilic oesophagitis (discovery cohort), using the eosinophilic oesophagitis diagnostic panel (EDP), a set of 96 informative transcripts. Histological and endoscopic features were assessed by quantification of oesophageal eosinophils and use of the eosinophilic oesophagitis histology scoring system (HSS) and the eosinophilic oesophagitis endoscopic reference score (EREFS). Associations among the various histological, endoscopic, and molecular features were analysed by Spearman correlation. Results were replicated in a biologically independent, single-centre, validation cohort of patients with active eosinophilic oesophagitis.
FINDINGS: The discovery cohort contained 185 samples and the validation cohort comprised 100 specimens. In the discovery cohort, EDP showed intersite consistency, significant correlation with oesophageal eosinophils (p<0·0001), and similar findings between paediatric and adult patients. Of eight HSS domains, basal zone hyperplasia correlated with the EDP (median Spearman ρ 0·47 [IQR 0·36-0·60]). Of five EREFS features, distal furrows correlated with the EDP (median Spearman ρ 0·42 [0·32-0·50]). By analysing active eosinophilic oesophagitis in the discovery cohort, the EDP identified three clusters associated with distinct endotypes (termed EoEe1-3) despite similar eosinophil levels. EoEe1 was associated with a normal-appearing oesophagus (risk ratio [RR] 3·27, 95% CI 1·04-10·27; p=0·0443), an inverse association with a history of oesophageal dilation (0·27, 0·09-0·82; p=0·0105) and showed relatively mild histological, endoscopic, and molecular changes. EoEe2 showed an inflammatory and steroid-refractory phenotype (RR 2·77, 95% CI 1·11-6·95; p=0·0376) and had the highest expression of inflammatory cytokines and steroid-responding genes. EoEe3 was associated with a narrow-calibre oesophagus (RR 7·98, 95% CI 1·84-34·64; p=0·0013) and adult onset (2·22, 1·19-4·12; p=0·0155), and showed the highest degree of endoscopic and histological severity and the lowest expression of epithelial differentiation genes. These endotypes were replicated in the validation cohort by clustering and with an eosinophilic oesophagitis endotype-prediction algorithm.
INTERPRETATION: Our new disease classification stratifies patients with eosinophilic oesophagitis into subgroups with potential clinical and therapeutic significance and provides a framework for a precision medicine approach to eosinophilic oesophagitis. FUNDING: National Institutes of Health.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29730081      PMCID: PMC5997568          DOI: 10.1016/S2468-1253(18)30096-7

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


  28 in total

1.  Long-Term Treatment of Eosinophilic Esophagitis With Swallowed Topical Corticosteroids: Development and Evaluation of a Therapeutic Concept.

Authors:  Thomas Greuter; Christian Bussmann; Ekaterina Safroneeva; Alain M Schoepfer; Luc Biedermann; Stephan R Vavricka; Alex Straumann
Journal:  Am J Gastroenterol       Date:  2017-07-18       Impact factor: 10.864

2.  Effects of an anti-TSLP antibody on allergen-induced asthmatic responses.

Authors:  Gail M Gauvreau; Paul M O'Byrne; Louis-Philippe Boulet; Ying Wang; Donald Cockcroft; Jeannette Bigler; J Mark FitzGerald; Michael Boedigheimer; Beth E Davis; Clapton Dias; Kevin S Gorski; Lynn Smith; Edgar Bautista; Michael R Comeau; Richard Leigh; Jane R Parnes
Journal:  N Engl J Med       Date:  2014-05-20       Impact factor: 91.245

3.  Clinicopathologic and gene expression analysis of initial biopsies from patients with eosinophilic esophagitis refractory to therapy.

Authors:  Ayesha S Siddique; David C Corney; Shamlal Mangray; Kara A Lombardo; Sonja Chen; Alexander S Marwaha; Murray B Resnick; Michael Herzlinger; Andres Matoso
Journal:  Hum Pathol       Date:  2017-09-04       Impact factor: 3.466

4.  Elevated levels of leukotriene C4 synthase mRNA distinguish a subpopulation of eosinophilic oesophagitis patients.

Authors:  W S Lexmond; M Pardo; K Rooney; J A Goettel; S B Snapper; E H Yen; E Dehlink; S Nurko; E Fiebiger
Journal:  Clin Exp Allergy       Date:  2013-08       Impact factor: 5.018

5.  Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner.

Authors:  Alain M Schoepfer; Ekaterina Safroneeva; Christian Bussmann; Tanja Kuchen; Susanne Portmann; Hans-Uwe Simon; Alex Straumann
Journal:  Gastroenterology       Date:  2013-08-13       Impact factor: 22.682

6.  Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis.

Authors:  Marc E Rothenberg; Ting Wen; Allison Greenberg; Oral Alpan; Benjamin Enav; Ikuo Hirano; Kari Nadeau; Sergio Kaiser; Thomas Peters; Antonio Perez; Ieuan Jones; Jonathan P Arm; Robert M Strieter; Ronald Sabo; Kulasiri A Gunawardena
Journal:  J Allergy Clin Immunol       Date:  2014-09-13       Impact factor: 10.793

7.  Cross-sector sponsorship of research in eosinophilic esophagitis: a collaborative model for rational drug development in rare diseases.

Authors:  Robert Fiorentino; Gumei Liu; Anne R Pariser; Andrew E Mulberg
Journal:  J Allergy Clin Immunol       Date:  2012-07-31       Impact factor: 10.793

8.  Early Comparison of Inflammatory vs. Fibrostenotic Phenotype in Eosinophilic Esophagitis in a Multicenter Longitudinal Study.

Authors:  Manish B Singla; Mirna Chehade; Diana Brizuela; Corinne L Maydonovitch; Yen-Ju Chen; Mary Ellen Riffle; Sami R Achem; Fouad J Moawad
Journal:  Clin Transl Gastroenterol       Date:  2015-12-17       Impact factor: 4.488

9.  Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial.

Authors:  Sandra Andorf; Natasha Purington; Whitney M Block; Andrew J Long; Dana Tupa; Erica Brittain; Amanda Rudman Spergel; Manisha Desai; Stephen J Galli; Kari C Nadeau; R Sharon Chinthrajah
Journal:  Lancet Gastroenterol Hepatol       Date:  2017-12-12

10.  Creating a multi-center rare disease consortium - the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR).

Authors:  Katherine Cheng; Sandeep K Gupta; Susanna Kantor; Jonathan T Kuhl; Seema S Aceves; Peter A Bonis; Kelley E Capocelli; Christina Carpenter; Mirna Chehade; Margaret H Collins; Evan S Dellon; Gary W Falk; Rashmi Gopal-Srivastava; Nirmala Gonsalves; Ikuo Hirano; Eileen C King; John Leung; Jeffrey P Krischer; Vincent A Mukkada; Alain Schoepfer; Jonathan M Spergel; Alex Straumann; Guang-Yu Yang; Glenn T Furuta; Marc E Rothenberg
Journal:  Transl Sci Rare Dis       Date:  2017-12-18
View more
  47 in total

Review 1.  Role of genetics, environment, and their interactions in the pathogenesis of eosinophilic esophagitis.

Authors:  John Lyles; Marc Rothenberg
Journal:  Curr Opin Immunol       Date:  2019-05-25       Impact factor: 7.486

2.  Alignment of parent- and child-reported outcomes and histology in eosinophilic esophagitis across multiple CEGIR sites.

Authors:  Seema S Aceves; Eileen King; Margaret H Collins; Guang-Yu Yang; Kelley E Capocelli; J Pablo Abonia; Dan Atkins; Peter A Bonis; Christina L Carpenter; Evan S Dellon; Michael D Eby; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; Ikuo Hirano; Kendra Kocher; Jeffrey P Krischer; John Leung; Jessi Lipscomb; Paul Menard-Katcher; Vincent A Mukkada; Zhaoxing Pan; Jonathan M Spergel; Qin Sun; Barry K Wershil; Marc E Rothenberg; Glenn T Furuta
Journal:  J Allergy Clin Immunol       Date:  2018-05-29       Impact factor: 10.793

Review 3.  Eosinophilic esophagitis: pathophysiology and its clinical implications.

Authors:  Eisuke Inage; Glenn T Furuta; Calies Menard-Katcher; Joanne C Masterson
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-09-13       Impact factor: 4.052

Review 4.  Emerging therapies for eosinophilic esophagitis.

Authors:  Thomas Greuter; Ikuo Hirano; Evan S Dellon
Journal:  J Allergy Clin Immunol       Date:  2019-11-06       Impact factor: 10.793

5.  Eosinophil progenitor levels correlate with tissue pathology in pediatric eosinophilic esophagitis.

Authors:  Justin T Schwartz; David W Morris; Margaret H Collins; Marc E Rothenberg; Patricia C Fulkerson
Journal:  J Allergy Clin Immunol       Date:  2018-11-09       Impact factor: 10.793

6.  Identification of anoctamin 1 (ANO1) as a key driver of esophageal epithelial proliferation in eosinophilic esophagitis.

Authors:  Simone Vanoni; Chang Zeng; Sahiti Marella; Jazib Uddin; David Wu; Kavisha Arora; Catherine Ptaschinski; Jianwen Que; Taeko Noah; Lisa Waggoner; Artem Barski; Andrey Kartashov; Mark Rochman; Ting Wen; Lisa Martin; Jason Spence; Margaret Collins; Vincent Mukkada; Phillip Putnam; Anjaparavanda Naren; Mirna Chehade; Marc E Rothenberg; Simon P Hogan
Journal:  J Allergy Clin Immunol       Date:  2019-10-21       Impact factor: 10.793

Review 7.  Eosinophilic Esophagitis: Existing and Upcoming Therapies in an Age of Emerging Molecular and Personalized Medicine.

Authors:  Ian F Slack; Justin T Schwartz; Vincent A Mukkada; Shawna Hottinger; J Pablo Abonia
Journal:  Curr Allergy Asthma Rep       Date:  2020-06-06       Impact factor: 4.806

Review 8.  Allergies and Eosinophilic Esophagitis-Current Updates for the Pediatric Gastroenterologist.

Authors:  Prerana Williamson; Seema Aceves
Journal:  Curr Gastroenterol Rep       Date:  2019-11-20

9.  New developments in patients with eosinophilic gastrointestinal diseases presented at the CEGIR/TIGERS Symposium at the 2018 American Academy of Allergy, Asthma & Immunology Meeting.

Authors:  Jonathan M Spergel; Seema S Aceves; Kara Kliewer; Nirmala Gonsalves; Mirna Chehade; Joshua B Wechsler; Marion Groetch; Joshua Friedlander; Evan S Dellon; Wendy Book; Ikuo Hirano; Amanda B Muir; Antonella Cianferoni; Lisa Spencer; Chris A Liacouras; Edaire Cheng; Leah Kottyan; Ting Wen; Thomas Platts-Mills; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2018-05-24       Impact factor: 10.793

10.  Consortium of Eosinophilic Gastrointestinal Disease Researchers: Advancing the Field of Eosinophilic GI Disorders Through Collaboration.

Authors:  Sandeep K Gupta; Gary W Falk; Seema S Aceves; Mirna Chehade; Margaret H Collins; Evan S Dellon; Nirmala Gonsalves; Ikuo Hirano; Vincent A Mukkuda; Kathryn A Peterson; Jonathan Spergel; Guang-Yu Yang; Glenn T Furuta; Marc E Rothenberg
Journal:  Gastroenterology       Date:  2018-11-17       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.